Recently, Salubris announced that phase 1 trial of JK08 has been initiated after the submission of CTA (European Clinical Trial Application), and recruiting is now ongoing. JK08 is independently developed by its subsidiary Salubris Biotherapeutics, Inc. (SalubrisBio).
JK08 is a fusion protein of IL-15/IL-15Rα complex and anti-CTLA-4 antibody. It is an innovative first-in-class anti-tumor biologics developed by SalubrisBio with intellectual property rights, which is intended for the treatment of advanced solid tumors.
As a monotherapy, JK08 showed a longer serum half-life and response duration. If JK08 can be successfully developed and approved for marketing, it is expected to reduce the frequency of drug administration, make drug administration more convenient, improve patients' compliance, and have great development potential.